# Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

> **NCT07551414** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 38 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Carcinoma)
- Leptomeningeal Metastasis
- EGFR-TKI Sensitizing Mutation
- Zorifertinib

## Interventions

- **DRUG:** Zorifertinib Plus Intra-Ommaya CSF Chemotherapy

## Key facts

- **NCT ID:** NCT07551414
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2027-05-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07551414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07551414, "Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT07551414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*